Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia : Results from the ECMM Candida III Multinational European Observational Cohort Study
© 2023. The Author(s)..
BACKGROUND: To date, azoles represent the only viable option for oral treatment of invasive Candida infections, while rates of azole resistance among non-albicans Candida spp. continue to increase. The objective of this sub-analysis of the European multicenter observational cohort study Candida III was to describe demographical and clinical characteristics of the cohort requiring prolonged hospitalization solely to complete intravenous (iv) antifungal treatment (AF Tx).
METHODS: Each participating hospital (number of eligible hospitals per country determined by population size) included the first ~ 10 blood culture proven adult candidemia cases occurring consecutively after July 1st, 2018, and treating physicians answered the question on whether hospital stay was prolonged only for completion of intravenous antifungal therapy. Descriptive analyses as well as binary logistic regression was used to assess for predictors of prolonged hospitalization solely to complete iv AF Tx.
FINDINGS: Hospital stay was prolonged solely for the completion of iv AF Tx in 16% (100/621) of candidemia cases by a median of 16 days (IQR 8 - 28). In the multivariable model, initial echinocandin treatment was a positive predictor for prolonged hospitalization to complete iv AF Tx (aOR 2.87, 95% CI 1.55 - 5.32, p < 0.001), while (i) neutropenia, (ii) intensive care unit admission, (iii) catheter related candidemia, (iv) total parenteral nutrition, and (v) C. parapsilosis as causative pathogen were found to be negative predictors (aOR 0.22 - 0.45; p < 0.03).
INTERPRETATION: Hospital stays were prolonged due to need of iv AF Tx in 16% of patients with candidemia. Those patients were more likely to receive echinocandins as initial treatment and were less severely ill and less likely infected with C. parapsilosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
|---|---|
| Enthalten in: |
Mycopathologia - 188(2023), 6 vom: 11. Dez., Seite 983-994 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 01.12.2023 Date Revised 01.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11046-023-00776-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360657397 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360657397 | ||
| 003 | DE-627 | ||
| 005 | 20231226083457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11046-023-00776-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360657397 | ||
| 035 | |a (NLM)37566212 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Egger, Matthias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia |b Results from the ECMM Candida III Multinational European Observational Cohort Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2023 | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: To date, azoles represent the only viable option for oral treatment of invasive Candida infections, while rates of azole resistance among non-albicans Candida spp. continue to increase. The objective of this sub-analysis of the European multicenter observational cohort study Candida III was to describe demographical and clinical characteristics of the cohort requiring prolonged hospitalization solely to complete intravenous (iv) antifungal treatment (AF Tx) | ||
| 520 | |a METHODS: Each participating hospital (number of eligible hospitals per country determined by population size) included the first ~ 10 blood culture proven adult candidemia cases occurring consecutively after July 1st, 2018, and treating physicians answered the question on whether hospital stay was prolonged only for completion of intravenous antifungal therapy. Descriptive analyses as well as binary logistic regression was used to assess for predictors of prolonged hospitalization solely to complete iv AF Tx | ||
| 520 | |a FINDINGS: Hospital stay was prolonged solely for the completion of iv AF Tx in 16% (100/621) of candidemia cases by a median of 16 days (IQR 8 - 28). In the multivariable model, initial echinocandin treatment was a positive predictor for prolonged hospitalization to complete iv AF Tx (aOR 2.87, 95% CI 1.55 - 5.32, p < 0.001), while (i) neutropenia, (ii) intensive care unit admission, (iii) catheter related candidemia, (iv) total parenteral nutrition, and (v) C. parapsilosis as causative pathogen were found to be negative predictors (aOR 0.22 - 0.45; p < 0.03) | ||
| 520 | |a INTERPRETATION: Hospital stays were prolonged due to need of iv AF Tx in 16% of patients with candidemia. Those patients were more likely to receive echinocandins as initial treatment and were less severely ill and less likely infected with C. parapsilosis | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Candida albicans | |
| 650 | 4 | |a Candida auris | |
| 650 | 4 | |a Candida glabrata | |
| 650 | 4 | |a Candida parapsilosis | |
| 650 | 4 | |a Candida tropicalis | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Mortality | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Echinocandins |2 NLM | |
| 650 | 7 | |a Azoles |2 NLM | |
| 700 | 1 | |a Salmanton-García, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Barac, Aleksandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gangneux, Jean-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Guegan, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Arsic-Arsenijevic, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Matos, Tadeja |e verfasserin |4 aut | |
| 700 | 1 | |a Tomazin, Rok |e verfasserin |4 aut | |
| 700 | 1 | |a Klimko, Nikolai |e verfasserin |4 aut | |
| 700 | 1 | |a Bassetti, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Hammarström, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Meijer, Eelco F J |e verfasserin |4 aut | |
| 700 | 1 | |a Meis, Jacques F |e verfasserin |4 aut | |
| 700 | 1 | |a Prattes, Juergen |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Resat Sipahi, Oguz |e verfasserin |4 aut | |
| 700 | 1 | |a Scharmann, Ulrike |e verfasserin |4 aut | |
| 700 | 1 | |a White, P Lewis |e verfasserin |4 aut | |
| 700 | 1 | |a Desoubeaux, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a García-Rodríguez, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Vidal, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Pérez, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Maite |e verfasserin |4 aut | |
| 700 | 1 | |a Tumbarello, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Talento, Alida Fe |e verfasserin |4 aut | |
| 700 | 1 | |a Rogers, Benedict |e verfasserin |4 aut | |
| 700 | 1 | |a Lagrou, Katrien |e verfasserin |4 aut | |
| 700 | 1 | |a van Praet, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Arikan-Akdagli, Sevtap |e verfasserin |4 aut | |
| 700 | 1 | |a Arendrup, Maiken C |e verfasserin |4 aut | |
| 700 | 1 | |a Koehler, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Cornely, Oliver A |e verfasserin |4 aut | |
| 700 | 1 | |a Hoenigl, Martin |e verfasserin |4 aut | |
| 700 | 0 | |a ECMM Candida III Study Group$ |e verfasserin |4 aut | |
| 700 | 1 | |a Alastruey-Izquierdo, Ana |e investigator |4 oth | |
| 700 | 1 | |a de Jonge, Nick Alexander |e investigator |4 oth | |
| 700 | 1 | |a Bicanic, Tihana |e investigator |4 oth | |
| 700 | 1 | |a Blennow, Ola |e investigator |4 oth | |
| 700 | 1 | |a Denis, Blandine |e investigator |4 oth | |
| 700 | 1 | |a Khanna, Nina |e investigator |4 oth | |
| 700 | 1 | |a Lass-Flörl, Cornelia |e investigator |4 oth | |
| 700 | 1 | |a Logan, Clare |e investigator |4 oth | |
| 700 | 1 | |a Loughlin, Laura |e investigator |4 oth | |
| 700 | 1 | |a Özenci, Volkan |e investigator |4 oth | |
| 700 | 1 | |a Zdenek, Zdenek |e investigator |4 oth | |
| 700 | 1 | |a Rahimli, Laman |e investigator |4 oth | |
| 700 | 1 | |a Rautemaa-Richardson, Riina |e investigator |4 oth | |
| 700 | 1 | |a Steinmann, Joerg |e investigator |4 oth | |
| 700 | 1 | |a Stoma, Igor |e investigator |4 oth | |
| 700 | 1 | |a Trauth, Janina |e investigator |4 oth | |
| 700 | 1 | |a Danion, François |e investigator |4 oth | |
| 700 | 1 | |a Buil, Jochem B |e investigator |4 oth | |
| 700 | 1 | |a Dávila-Valls, Julio |e investigator |4 oth | |
| 700 | 1 | |a van Wijngaerden, Eric |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Mycopathologia |d 1975 |g 188(2023), 6 vom: 11. Dez., Seite 983-994 |w (DE-627)NLM000021288 |x 1573-0832 |7 nnns |
| 773 | 1 | 8 | |g volume:188 |g year:2023 |g number:6 |g day:11 |g month:12 |g pages:983-994 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11046-023-00776-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 188 |j 2023 |e 6 |b 11 |c 12 |h 983-994 | ||